Related Experiment Video
Updated: Sep 21, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
Cardiac angiosarcoma: A diagnostic and therapeutic challenge
Tharani Krishnan1, Gosta Pettersson2, Rahul Mukherjee3
1Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Abstract:
Cardiac angiosarcomas are a rare group of soft tissue sarcomas, characterized by aggressive local growth and early spread. Because this is an uncommon disease, there is currently no standard treatment approach. When localized, surgery appears to lead to the best outcomes, but this can be technically challenging and not always feasible. Upfront chemoradiotherapy provides an alternative that may shrink the tumor to enable definitive surgical resection. We report a case of primary cardiac angiosarcoma with a complete metabolic and pathological response after upfront chemoradiotherapy with paclitaxel, who then underwent surgery, as a potential treatment option for patients with this rare condition. <Learning objective: Cardiac angiosarcoma can present with non-specific symptoms and signs making early diagnosis difficult. When localized, surgery provides the best survival outcomes for patients, but may not be possible due to the extent of invasion into surrounding critical structures. In this case of locally advanced disease in a young patient, there was the opportunity to treat this tumor aggressively with upfront combined chemoradiotherapy followed by surgery, with a dramatic response observed.>.
Insights
Cardiac angiosarcoma, a rare cancer, showed a complete response to upfront chemoradiotherapy with paclitaxel and surgery. This combined approach offers a potential treatment for this aggressive disease.
Area of Science:
- Oncology
- Cardiovascular Surgery
- Radiotherapy
Background:
- Cardiac angiosarcomas are rare, aggressive soft tissue sarcomas with no standard treatment.
- Surgical resection offers the best outcomes for localized disease but is often technically challenging or infeasible.
- Upfront chemoradiotherapy is an alternative to shrink tumors for subsequent surgical resection.
Observation:
- A case of primary cardiac angiosarcoma in a young patient with locally advanced disease is presented.
- The patient received upfront chemoradiotherapy with paclitaxel.
- A complete metabolic and pathological response was observed post-treatment.
Findings:
- Upfront chemoradiotherapy with paclitaxel led to a dramatic tumor response.
- The patient subsequently underwent successful surgical resection.
- This multimodal approach resulted in a complete pathological response.
Implications:
- This case highlights upfront chemoradiotherapy followed by surgery as a viable treatment strategy for cardiac angiosarcoma.
- This aggressive, combined treatment approach may improve outcomes for patients with this rare and challenging condition.
- Further research into neoadjuvant therapies for cardiac angiosarcoma is warranted.
More Related Videos
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
06:03Development and Angiographic Use of the Rabbit VX2 Model for Liver Cancer
Published on: January 7, 2019
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care